Anticholinesterase Inhibitors

Anticholinesterase drugs, or cholinesterase inhibitors, are agents that block the enzyme acetylcholinesterase (and in some cases butyrylcholinesterase), reducing the breakdown of acetylcholine and so raising and prolonging its concentration at cholinergic synapses. Because they amplify endogenous cholinergic transmission rather than activating receptors directly, they act as indirect cholinomimetics. The class spans reversible inhibitors used therapeutically and irreversible organophosphorus inhibitors that are central to toxicology.

Definition

Anticholinesterase drugs are inhibitors of acetylcholinesterase (and sometimes butyrylcholinesterase) that slow the hydrolysis of acetylcholine, thereby increasing its synaptic concentration and indirectly enhancing cholinergic transmission.

Scope

The entry covers the mechanism of cholinesterase inhibition, the distinction between reversible inhibitors (such as physostigmine, neostigmine, pyridostigmine, and the centrally acting agents donepezil, rivastigmine, and galantamine) and irreversible organophosphorus inhibitors, and the resulting amplification of cholinergic signalling at muscarinic and nicotinic sites. It treats both the therapeutic class and its toxicological counterpart at a conceptual level, without dosing or individualized treatment guidance.

Core questions

• Is the inhibitor reversible or irreversible, and how does that govern duration of action and recovery?
• Does the agent cross into the central nervous system, and how does that determine whether its effects are peripheral or central?
• How does the same mechanism that underlies therapeutic use also account for organophosphate toxicity?

Key concepts

• Acetylcholinesterase and butyrylcholinesterase
• Reversible versus irreversible inhibition
• Carbamate inhibitors (physostigmine, neostigmine, pyridostigmine)
• Centrally acting inhibitors (donepezil, rivastigmine, galantamine)
• Organophosphorus inhibitors and enzyme aging
• Indirect (acetylcholine-amplifying) cholinomimetic action

Mechanisms

Acetylcholinesterase normally terminates cholinergic signalling by hydrolyzing acetylcholine in the synaptic cleft. Anticholinesterase drugs occupy or modify the enzyme's active site, slowing hydrolysis and allowing acetylcholine to accumulate and act for longer at both muscarinic and nicotinic receptors. Reversible inhibitors, including carbamates such as neostigmine and centrally penetrant agents such as donepezil, dissociate from the enzyme over time. Irreversible organophosphorus inhibitors form a covalent bond that, after a process called aging, becomes essentially permanent, producing prolonged and potentially life-threatening cholinergic excess (Dale, 1934; Eddleston et al., 2008; Brunton et al., 2018).

Clinical relevance

Cholinesterase inhibitors appear across several areas described in the literature, including symptomatic treatment of Alzheimer's disease (Birks, 2006) and reversal of certain neuromuscular block, while the same mechanism underlies organophosphate and carbamate poisoning in toxicology (Eddleston et al., 2008). This entry explains the shared mechanism for educational purposes and is not a basis for dosing or individual treatment decisions.

Epidemiology

Acute organophosphorus pesticide poisoning, which acts through irreversible cholinesterase inhibition, is described as a major cause of poisoning death worldwide, with a particularly heavy burden in agricultural regions of low- and middle-income countries (Eddleston et al., 2008).

Evidence & guidelines

Systematic-review evidence addresses the cholinesterase-inhibitor class in Alzheimer's disease, examining cognitive and global outcomes (Birks, 2006), while management of organophosphate poisoning is summarized in clinical reviews (Eddleston et al., 2008). The underlying mechanism rests on classic work on cholinergic transmission (Dale, 1934) and is consolidated in standard pharmacology references (Brunton et al., 2018).

History

Physostigmine, an alkaloid from the Calabar bean, was the prototype reversible cholinesterase inhibitor and helped establish the concept of indirect cholinomimetic action. The synthesis of organophosphorus compounds in the mid-twentieth century produced both potent irreversible inhibitors used as pesticides and the toxicological understanding of cholinergic crisis, while later decades introduced centrally acting reversible inhibitors investigated for cognitive disorders (Birks, 2006; Eddleston et al., 2008).

Debates

How clinically meaningful is the benefit of cholinesterase inhibitors in Alzheimer's disease?

Systematic-review evidence shows measurable effects on cognitive and global measures, but the size and clinical significance of the benefit, balanced against adverse effects, remain a matter of ongoing discussion in the literature.

Key figures

• Henry Hallett Dale
• Michael Eddleston

Seminal works

• dale-1934
• eddleston-2008
• birks-2006

Frequently asked questions

Why are cholinesterase inhibitors called indirect cholinomimetics?

They do not activate cholinergic receptors themselves; instead they block the enzyme that breaks down acetylcholine, so that the body's own acetylcholine accumulates and produces enhanced cholinergic effects.

What is the difference between reversible and irreversible cholinesterase inhibitors?

Reversible inhibitors bind the enzyme temporarily and dissociate over minutes to hours, whereas irreversible organophosphorus inhibitors form a covalent bond that, after aging, makes the enzyme essentially permanently inactive until new enzyme is synthesized.